Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor.
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Peptide radiopharmaceuticals are potential imaging agents for brain disorders, should these agents be enabled to undergo transport through the blood-brain barrier (BBB) in vivo. Radiolabeled Abeta1-40 images brain amyloid in tissue sections of Alzheimer's disease autopsy brain, but this peptide radiopharmaceutical cannot be used to image brain amyloid in vivo owing to negligible transport through the BBB. In these studies, 125I-Abeta1-40 was monobiotinylated (bio) and conjugated to a BBB drug delivery and brain targeting system comprised of a complex of the 83-14 monoclonal antibody (mAb) to the human insulin receptor, which is tagged with streptavidin (SA). A marked increase in rhesus monkey brain uptake of the 125I-bio-Abeta1-40 was observed after conjugation to the 8314-SA delivery system at 3 h after intravenous injection. In contrast, no measurable brain uptake of 125I-bio-Abeta1-40 was observed in the absence of a BBB drug delivery system. The peptide radiopharmaceutical was degraded in brain with export of the iodide radioactivity, and by 48 h after intravenous injection, 90% of the radioactivity was cleared from the brain. In conclusion, these studies describe a methodology for BBB drug delivery and brain targeting of peptide radiopharmaceuticals that could be used for imaging amyloid or other brain disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor
Kang, J., Lemaire, H.-G., Unterbeck, A., Salbaum, J. M., Masters, C. L., Grzeschik, K.-H., Multhaup, G., Beyreuther, K., & Müller-Hill, B. (1987) · Nature · doi:10.1038/325733a0 · Cited by 4,619
Amyloid plaque core protein in Alzheimer disease and Down syndrome.
Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., McDonald, B. L., & Beyreuther, K. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.12.4245 · Cited by 4,431
Jarrett, J. T., & Lansbury, P. T. (1993) · Cell · doi:10.1016/0092-8674(93)90635-4 · Cited by 2,178
Observations on the brains of demented old people
Tomlinson, B. E., Blessed, G., & Roth, M. (1970) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(70)90063-8 · Cited by 2,084
Transferrin receptor on endothelium of brain capillaries
Jefferies, W. A., Brandon, M. R., Hunt, S. V., Williams, A. F., Gatter, K. C., & Mason, D. Y. (1984) · Nature · doi:10.1038/312162a0 · Cited by 1,061 · cited 1×
“These results are similar to previously reported emulsion and film autoradiography experiments demonstrating binding of (125)I-bio-Ab to amyloid plaques of sections of Alzheimer’s disease brain after conjugation of the peptide pharmaceutical to a conjugate of SA and the OX26 mAb (16), which is a murine mAb to the rat…”
ResultRoher, A. E., Lowenson, J. D., Clarke, S., Woods, A. S., Cotter, R. J., Gowing, E., & Ball, M. J. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.22.10836 · Cited by 740
Water-soluble Aβ(N-40, N-42) oligomers in normal and Alzheimer disease brains
Kuo, Y.-M., Emmerling, M. R., Vigo-Pelfrey, C., Kasunic, T. C., Kirkpatrick, J. B., Murdoch, G. H., Ball, M. J., & Roher, A. E. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.8.4077 · Cited by 618 · cited 1×
“The Ab plaque may constitute up to 15% of the brain volume in Alzheimer’s disease (41).”
BackgroundAmyloid β-Peptide Is Transported on Lipoproteins and Albumin in Human Plasma
Biere, A. L., Ostaszewski, B., Stimson, E. R., Hyman, B. T., Maggio, J. E., & Selkoe, D. J. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.51.32916 · Cited by 331 · cited 1×
“90% bound by human albumin (33), this binding is relatively weak in vivo and does not inhibit the rapid clearance of (125)I-bio-Ab in vivo (Fig.”
BackgroundGhersi‐Egea, J. ‐., Gorevic, P. D., Ghiso, J., Frangione, B., Patlak, C. S., & Fenstermacher, J. D. (1996) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1996.67020880.x · Cited by 222 · cited 1×
“The absorption of Ab to meningeal vascular surfaces has also been demonstrated in vivo in the rat (36).”
BackgroundNeuropathology and apolipoprotein E profile of aged chimpanzees: implications for Alzheimer disease.
Gearing, M., Rebeck, G. W., Hyman, B. T., Tigges, J., & Mirra, S. S. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.20.9382 · Cited by 179
Cited by
Drug Transport across the Blood–Brain Barrier
Pardridge, W. M. (2012) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2012.126 · Cited by 1,994
Self-citationSignals That Regulate Food Intake and Energy Homeostasis
Woods, S. C., Seeley, R. J., Porte, D., & Schwartz, M. W. (1998) · Science · doi:10.1126/science.280.5368.1378 · Cited by 1,169
Modern methods for delivery of drugs across the blood–brain barrier
Chen, Y., & Liu, L. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.11.010 · Cited by 1,006
Blood–Brain Barrier Transport of Therapeutics via Receptor-Mediation
Jones, A. R., & Shusta, E. V. (2007) · Pharmaceutical Research · doi:10.1007/s11095-007-9379-0 · Cited by 549
“Brain uptake was tested by intravenous injection into Rhesus monkeys, and like the situation observed in the mouse with 8D3 as a delivery vector, an increase in brain concentration of radiolabeled Aβ1–40 was observed when conjugated to 83-14 (61).”
BackgroundMethodProgress and perspectives on targeting nanoparticles for brain drug delivery
Gao, H. (2016) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2016.05.013 · Cited by 495
Nanotechnological advances for the delivery of cns therapeutics.
Wong, H. L., Wu, X. Y., & Bendayan, R. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.10.007 · Cited by 488
Strategies to advance translational research into brain barriers
Neuwelt, E., Abbott, N. J., Abrey, L., Banks, W. A., Blakley, B., Davis, T., Engelhardt, B., Grammas, P., Nedergaard, M., Nutt, J., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70326-5 · Cited by 474
Self-citationPardridge, W. M. (2007) · Pharmaceutical Research · doi:10.1007/s11095-007-9324-2 · Cited by 447
Self-citationde Boer, A. G., & Gaillard, P. J. (2007) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.47.120505.105237 · Cited by 348
Model for the regulation of energy balance and adiposity by the central nervous system
Schwartz, M. W., Baskin, D. G., Kaiyala, K. J., & Woods, S. C. (1999) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/69.4.584 · Cited by 325
Lee, H. J., Engelhardt, B., Lesley, J., Bickel, U., & Pardridge, W. M. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35388-1 · Cited by 287
Self-citationDiscovery of Novel Blood-Brain Barrier Targets to Enhance Brain Uptake of Therapeutic Antibodies
Zuchero, Y. J. Y., Chen, X., Bien-Ly, N., Bumbaca, D., Tong, R. K., Gao, X., Zhang, S., Hoyte, K., Luk, W., Huntley, M. A., et al. (2016) · Neuron · doi:10.1016/j.neuron.2015.11.024 · Cited by 282
A Historical Review of Brain Drug Delivery
Pardridge, W. M. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14061283 · Cited by 219
Self-citationDendrimer Advances for the Central Nervous System Delivery of Therapeutics
Xu, L., Zhang, H., & Wu, Y. (2014) · ACS Chemical Neuroscience · doi:10.1021/cn400182z · Cited by 167
Delivery of Biologics Across the Blood–Brain Barrier with Molecular Trojan Horse Technology
Pardridge, W. M. (2017) · BioDrugs · doi:10.1007/s40259-017-0248-z · Cited by 152
“From [80] Biologics and the Blood–Brain Barrier”
MethodSelf-citationTashima, T. (2020) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c19-00854 · Cited by 120
Evolving new-age strategies to transport therapeutics across the blood-brain-barrier
Choudhari, M., Hejmady, S., Narayan Saha, R., Damle, S., Singhvi, G., Alexander, A., Kesharwani, P., & Kumar Dubey, S. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120351 · Cited by 74
Drug targeting strategies into the brain for treating neurological diseases
Barnabas, W. (2019) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2018.10.015 · Cited by 70
Metadata
- Authors
- Wu, D., Yang, J., & Pardridge, W. M.
- Venue
- Journal of Clinical Investigation
- Published
- 1997-10-01
- Volume
- 100
- Issue
- 7
- Pages
- 1804-1812
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W4255653564
- Cited by
- 142
- References
- 11
- FWCI
- 3.66
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.